Russell, James A.
Wellman, Hugh
Walley, Keith R.
Article History
Received: 28 August 2018
Accepted: 1 November 2018
First Online: 16 November 2018
Authors’ information
: Not applicable
: This study was approved by St. Paul’s Hospital/University of British Columbia Ethics Committee who deemed no consent was necessary.
: Not applicable
: Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to PCSK9 inhibitor(s) and sepsis and related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell is a founder, Director and shareholder in Cyon Therapeutics Inc. (developing a sepsis therapy (PCSK9 inhibitor)). Dr. Russell has share options in Leading Biosciences Inc. Dr. Russell is a shareholder in Molecular You Corp. Dr. Russell reports receiving consulting fees in the last 3 years from the following:OrderedList removedDr. Russell reports having received an investigator-initiated grant from Grifols (entitled “Is HBP a mechanism of albumin’s efficacy in human septic shock?”) that is provided to and administered by UBC.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.